Tirzepatide vs Amycretin

Tirzepatide and Amycretin are both research peptides studied across multiple applications, though they originate from different pharmaceutical lineages and engage distinct receptor targets. Tirzepatide, developed by Eli Lilly, is a dual GIP and GLP-1 receptor agonist, while Amycretin, from Novo Nordisk, is a unimolecular co-agonist of GLP-1 and amylin receptors. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps. Notably, Tirzepatide has advanced to FDA approval for type 2 diabetes and weight management, whereas Amycretin remains in earlier clinical development, with Phase 3 trials anticipated in 2026.

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) including severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that promotes albumin binding, enabling once-weekly dosing. Clinical trials consistently demonstrate it delivers the most substantial weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks.

Key claims: Superior weight loss compared to semaglutide; Improves blood sugar control; May improve liver fat / NASH.

Amycretin is a first-in-class unimolecular peptide co-agonist developed by Novo Nordisk that simultaneously activates both GLP-1 and amylin receptors from a single molecule. It is being developed primarily as an oral tablet for obesity treatment. In the Phase 2 REDEFINE 1 trial, oral amycretin produced up to 13.1% body weight loss at 36 weeks — remarkable for an oral peptide formulation. Unlike orforglipron (a small-molecule oral GLP-1 agonist), amycretin is a true peptide with dual receptor engagement. Phase 3 trials expected to begin in 2026.

Key claims: Produces significant weight loss via oral tablet; Dual GLP-1/amylin agonism is synergistic; Subcutaneous formulation also effective.

Both peptides are studied for metabolic health, reflecting their shared incretin-based mechanisms. Tirzepatide is also researched for weight management, leveraging its dual GIP/GLP-1 agonism to achieve substantial body weight reduction. Amycretin is additionally investigated for weight loss and obesity treatment, with its oral formulation offering a distinct advantage in patient compliance. While both target metabolic pathways, Tirzepatide's applications extend to type 2 diabetes and sleep apnea, whereas Amycretin's research is more narrowly focused on obesity, with potential for broader metabolic benefits pending further trials.

Safety profiles for both peptides reflect their GLP-1 agonist class effects, with notable differences in severity and frequency. For Tirzepatide, common adverse events (5% or more in trials) include abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, and vomiting. Serious but rare events include pancreatitis, gallbladder issues, and dehydration leading to kidney problems. A boxed warning exists for thyroid C-cell tumors based on rodent data, advising patients to monitor for neck lump, swallowing difficulty, hoarseness, or shortness of breath. For Amycretin, the most common adverse events are gastrointestinal—nausea, vomiting, and diarrhea—consistent with GLP-1 agonists. These effects are generally mild to moderate, occurring during dose escalation and diminishing with continued treatment. The Phase 1 trial (Gasiorek et al., Lancet 2025) reported that amycretin was generally well tolerated across dose ranges.